TuHURA Biosciences (NASDAQ: HURA) received written confirmation from Nasdaq on February 26, 2026 that it has regained compliance with the $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). The company’s closing bid price remained at $1.00 or higher for 11 consecutive business days, from February 10 through February 25, satisfying the rule’s continuous‑price test.
Prior to this development, TuHURA had been out of compliance for 35 consecutive business days in January 2026, trading below $1.00. Nasdaq granted the company a 180‑day grace period that expires on July 28, 2026, and had suggested a reverse stock split as a potential remedy if other measures failed. By meeting the bid‑price requirement, TuHURA eliminates the immediate risk of delisting and demonstrates its ability to meet exchange standards.
Regaining compliance supports the company’s broader financial strategy. TuHURA is currently burning cash, reporting a negative levered free cash flow of $24.74 million, and has raised $15.6 million through a registered direct offering to fund key milestones. The company’s pipeline remains a central focus, with IFX‑2.0 in a Phase 3 trial for Merkel cell carcinoma and TBS 2025 in a Phase 2 study for relapsed/refractory NPM1‑mutated acute myeloid leukemia. Additional antibody‑drug conjugate programs are also advancing.
Dr. James Bianco, President and CEO, said, "We are pleased to have regained full compliance with Nasdaq's listing standards and continue to remain fully focused on advancing our pipeline of assets." The statement underscores the company’s commitment to its development agenda while reassuring investors that regulatory compliance has been restored.
The event is a material regulatory milestone that mitigates delisting risk and reinforces investor confidence, but the company’s ongoing cash burn and valuation concerns highlight the need for continued progress in its clinical programs to sustain long‑term growth.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.